John Edward Irving

Address:

8757 Tom Noon Ave UNIT 101, Las Vegas, NV 89178

VIN:

3FAHP0JA6AR377333

Make:

FORD

Model:

FUSION

Year:

2010

Address:

4946 Volcanic Rock Ln, Las Vegas, NV 89122

VIN:

2D4GP44L07R235006

Make:

DODGE

Model:

GRAND CARAVAN

Year:

2007

US Patent:

6864053, Mar 8, 2005

Filed:

May 4, 2000

Appl. No.:

09/564857

Inventors:

John M. Irving - San Mateo CA, US
Kenneth Ho - San Mateo CA, US
Michael Mok - Palo Alto CA, US
Flavia Borellini - Foster City CA, US

Assignee:

Cell Genesys - Foster City CA

International Classification:

C12Q001/68

US Classification:

435 6, 435 4, 435 5, 435325

Abstract:

Detection of members of a conserved, dispersed gene family is used to ascertain levels of host cell genomic DNA in a sample.

US Patent:

7153650, Dec 26, 2006

Filed:

Mar 13, 2003

Appl. No.:

10/389431

Inventors:

Lawrence W. Stanton - Singapore, SG
Ralph Brandenberger - Menlo Park CA, US
Joseph D. Gold - San Francisco CA, US
John M. Irving - San Mateo CA, US
Ramkumar Mandalam - Union City CA, US
Michael Mok - Palo Alto CA, US

Assignee:

Geron Corporation - Menlo Park CA

International Classification:

C12Q 1/00
C12Q 1/68
G01N 33/53
C12N 5/00
C12N 5/02

US Classification:

435 4, 435 6, 435 71

Abstract:

This disclosure provides a system for qualifying embryonic stem cells intended for human therapy. A large-scale sequencing project has identified important markers that are characteristic of undifferentiated pluripotent cells. Combinations of these markers can be used to validate the self-renewing capacity of ES cells, and their ability to differentiate into tissue types suitable for regenerative medicine. The marker system of this invention has been used to screen feeder cells, media additives, and culture conditions that promote proliferation of stem cells without differentiation. A culture system optimized by following these markers is suitable for rapid expansion of undifferentiated cells from existing lines, or the derivation of new lines that are equally apposite for clinical use.

US Patent:

20030095989, May 22, 2003

Filed:

Dec 17, 2001

Appl. No.:

10/023969

Inventors:

John Irving - San Mateo CA, US
Jane Lebkowski - Portola Valley CA, US

International Classification:

A61K048/00
C12Q001/70
C12N007/01
C12N005/08
A01N063/00
A61K039/12
A61K039/245
A61K039/25
A61K039/23
A61K039/235
C12N007/00
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74
C12N005/00
C12N005/02

US Classification:

424/233100, 424/093600, 435/235100, 435/005000, 435/366000, 424/230100, 424/199100, 435/320100, 435/325000

Abstract:

Described in this disclosure is a system for gene therapy using a chimeric vector made from an adenovirus genome and a heterologous gene that functionally replaces an adenovirus gene required for replication or assembly. Cytolytic viruses can be produced that target particular tissue types by virtue of having replication controlled by a specific transcription control element—such as the promoter for telomerase reverse transcriptase. These therapeutic viruses are believed to have an improved safety and efficacy profile compared with previously available systems.

US Patent:

20030099616, May 29, 2003

Filed:

Jul 25, 2002

Appl. No.:

10/206447

Inventors:

John Irving - San Mateo CA, US
David Karpf - Monte Sereno CA, US
J. Schiff - Menlo Park CA, US

International Classification:

A61K048/00
C12N007/00
C12N015/861
C12N007/01

US Classification:

424/093200, 435/320100, 435/456000, 435/235100

Abstract:

It has been discovered that the specificity of multiple transcriptional regulatory elements can be combined to make vector systems that selectively target cancer cells. The promoter for telomerase reverse transcriptase (TERT) can be combined in a remarkably synergistic fashion with another promoter that has expression restricted to cancer cells or a particular tissue type. The two promoters work synergistically for exquisite targeting of the malignant cells—where it causes cell lysis while leaving neighboring healthy cells intact.

US Patent:

20030224411, Dec 4, 2003

Filed:

Mar 13, 2003

Appl. No.:

10/388578

Inventors:

Lawrence Stanton - Singapore, SG
Ralph Brandenberger - Menlo Park CA, US
Joseph Gold - San Francisco CA, US
John Irving - San Mateo CA, US
Ramkumar Mandalam - Union City CA, US
Michael Mok - Palo Alto CA, US
Dawne Shelton - Salt Lake City UT, US

International Classification:

C12Q001/68
G01N033/53
G01N033/567
C12N005/08

US Classification:

435/006000, 435/007200, 435/366000

Abstract:

Genes that are up- or down-regulated during differentiation provide important leverage by which to characterize and manipulate early-stage pluripotent stem cells. Over 35,000 unique transcripts have been amplified and sequenced from undifferentiated human embryonic stem cells, and three types of differentiated progeny. Statistical analysis of the assembled transcripts identified genes that alter expression levels as differentiation proceeds. The expression profile provides a marker system that has been used to identify particular culture components for maintaining the undifferentiated phenotype. The gene products can also be used to promote differentiation; to assess other relatively undifferentiated cells (such as cancer cells); to control gene expression; or to separate cells having desirable characteristics. Manipulation of particular genes can be used to forestall or focus the differentiation process, en route to producing a specialized homogenous cell population suitable for human therapy.

US Patent:

20060134636, Jun 22, 2006

Filed:

Mar 19, 2004

Appl. No.:

10/804822

Inventors:

Lawrence Stanton - Singapore, SG
Ralph Brandenberger - Menlo Park CA, US
Elisa Brunette - Redwood City CA, US
Joseph Gold - San Francisco CA, US
John Irving - San Mateo CA, US
Ramkumar Mandalam - Union City CA, US
Michael Mok - Palo Alto CA, US
Sandra Powell - Castro Valley CA, US

International Classification:

C12Q 1/68
G01N 33/567
C12N 5/08
G01N 33/53

US Classification:

435006000, 435366000, 435007200

Abstract:

This disclosure provides a system for qualifying embryonic stem cells intended for human therapy. A comprehensive sequencing project has identified important markers that are characteristic of undifferentiated pluripotent cells. Combinations of these markers have been used to screen feeder cells, media additives, and culture conditions that promote rapid expansion of stem cells without differentiation. By measuring undifferentiated stem cell markers, and markers formed by early progenitors such as stromal cells, the user can quantitate the proportion and extent of differentiation. This establishes standardized criteria for master cell banks and cell cultures that can then be used to produce therapeutic cell populations and medicaments for use in regenerative medicine.

US Patent:

20090263835, Oct 22, 2009

Filed:

Jun 19, 2009

Appl. No.:

12/487869

Inventors:

Lawrence W. Stanton - Singapore, SG
Ralph Brandenberger - Melno Park CA, US
Joseph D. Gold - San Francisco CA, US
John M. Irving - San Mateo CA, US
Ramkumar Mandalam - Union City CA, US
Michael Mok - Palo Alto CA, US
Dawne Shelton - Salt Lake City UT, US

International Classification:

G01N 33/53

US Classification:

435 721

Abstract:

Genes that are up- or down-regulated during differentiation provide important leverage by which to characterize and manipulate early-stage pluripotent stem cells. Over 35,000 unique transcripts have been amplified and sequenced from undifferentiated human embryonic stem cells, and three types of differentiated progeny. Statistical analysis of the assembled transcripts identified genes that alter expression levels as differentiation proceeds. The expression profile provides a marker system that has been used to identify particular culture components for maintaining the undifferentiated phenotype. The gene products can also be used to promote differentiation; to assess other relatively undifferentiated cells (such as cancer cells); to control gene expression; or to separate cells having desirable characteristics. Manipulation of particular genes can be used to forestall or focus the differentiation process, en route to producing a specialized homogenous cell population suitable for human therapy.